Form 4: Syndax Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4
Neil Gallagher, President and Head of R&D at Syndax Pharmaceuticals, sold 4,618 shares of common stock on February 10, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On February 10, 2025, Neil Gallagher, President and Head of R&D at Syndax Pharmaceuticals, sold 4,618 shares of common stock.
- The sale was executed at a price of $15.504 per share.
- The transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Gallagher directly owns 85,095 shares of Syndax Pharmaceuticals.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of stock sale transaction. |
| 02/12/2025 | Date of signature for the Form 4 filing. |
Keywords
Syndax Pharmaceuticals, Neil Gallagher, Form 4, Stock Sale, Tax Obligations, Restricted Stock Units, SNDX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.